Abstract: The present invention relates to a novel production method of 4,6-diaminoresorcin, and to 2-sulfonic acid-4,6-dinitroresorcin as its intermediate and salts thereof.

Abstract: Methods of making compositions including fluorinated peroxides are disclosed. The compositions are useful, for example, for reacting with organic compounds. In one embodiment, novel peroxides are provided.

Abstract: One embodiment of the invention is a composition that comprises a radioactive 32P or 33P phosphine oxide molecule. The said composition is designed to bind to the transient potential receptor-M8 (TRP-M8) receptor of cells. The radioactive 32P or 33P phosphine oxide ligand may be used for radioreceptor binding studies and for diagnostic studies of cancerous tissues. The TRP-M8 receptor is selectively expressed in malignant tissues such as prostate cancer cells. Affinity of the 32P or 33P phosphine oxide ligand for the TRP-M8 receptor confers selectively and specificity in delivering lethal radiation to the diseased cells.

Abstract: Methyl (R)-2-(R1OSO2)-2-(2-chlorophenyl)acetates useful as intermediates in the preparation of methyl (S)-2(2-chlorophenyl)-2-(4,5,6,7-tetrahydrothieno[3,2-c]-5-pyridyl)acetate.

Abstract: A description is given of processes for the preparation of mono- and bisacylphosphines and of mono- and bisacylphosphine oxides and mono- and bisacylphosphine sulfides, which comprises first reacting organic P-monohalogenophosphines or P,P-dihalogenophosphines, or mixtures thereof, with an alkali metal or magnesium in combination with lithium, where appropriate in the presence of a catalyst, and then carrying out the reaction with acid halides and, in the case of the process for the preparation of oxides, carrying out an oxidation step and, in the case of the preparation of sulfides, reacting the phosphines so obtained with sulfur. It is characteristic, inter alia, that the processes are carried out without isolation of the intermediates.

Abstract: The present invention relates to novel heterocyclic antagonists of Formula (I) and pharmaceutical compositions comprising said antagonists of the corticotropin releasing factor receptor (“CRF receptor”) useful for the treatment of depression, anxiety, affective disorders, feeding disorders, post-traumatic stress disorder, headache, drug addiction, inflammatory disorders, drug or alcohol withdrawal symptoms and other conditions the treatment of which can be effected by the antagonism of the CRF-1 receptor.

Abstract: In a method for making bisphosphonates by reacting a carbonyl compound with a phosphorus halide, the reaction is carried out in a solvent/carrier system which is a mixture of an amine hydrochloride, phosphorous acid and optionally phosphoric acid.

Abstract: The present invention is to provide methods for producing highly pure 4,4′-dihydroxydiphenyl sulfone monoethers advantageously in industrial production. In a process for producing a compound represented by Formula (1) (wherein, R1 and R2 are each independently halogen, alkyl having 1 to 8 carbons or alkenyl having 2 to 8 carbons; m and n are each independently 0 or an integer of 1 to 4; and R3 is alkyl having 1 to 8 carbons, alkenyl having 2 to 8 carbons, cycloalkyl having 3 to 8 carbons or optionally substituted aralkyl), (1) a pH adjustment is carried out twice or more in the purification process, (2) an excessive amount of alkyl halide used is removed, (3) a solvent, such as water, containing 0.05 ppm or less of iron components is used, (4) tanks with corrosion-resistant layers over the inner walls are used, (6) a chelating agent is added, and (7) a means of drying with mechanical stir is applied.

Abstract: The liquid ethereal medium or liquid hydrocarbyl medium of a solution or slurry of an alkali metal tetrakis(Faryl)borate is substituted with at least one halogenated hydrocarbon, without isolating the alkali metal tetrakis(Faryl)borate, to form a new slurry or solution. At least a portion of the new solution is mixed together with a salt selected from a) a protic ammonium salt, b) an onium salt, and c) a triarylmethyl salt, to produce a protic ammonium tetrakis(Faryl)borate, an onium tetrakis(Faryl)borate, or a triarylmethyl tetrakis(Faryl)borate.

Abstract: The invention includes pharmaceutically active compounds and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention are particularly useful for treatment or prophylaxis of undesired thrombosis.

Abstract: Chiral ligands and transition metal complexes based on such chiral ligands useful in asymmetric catalysis are disclosed. The chiral ligands include phospholanes, P,N ligands, N,N ligands, biphenols, and chelating phosphines. The ferrocene-based irridium (R,R)-f-binaphane complex reduces imines to the corresponding amines with 95-99.6% enantioselectivity and reduces &bgr;-substituted-&agr;-arylenamides with 95% enantioselectivity. The transition metal complexes of the chiral ligands are useful in asymmetric reactions such as asymmetric hydrogenation of imines, asymmetric hydride transfer reactions, hydrosilylation, hydroboration, hydrovinylation, hydroformylation, allylic alkylation, cyclopropanation, Diels-Alder reaction, Heck reaction, isomerization, Aldol reaction, Michael addition and epoxidation reactions.

Abstract: After a fluoroaryl borane derivative is precipitated from a solution containing the fluoroaryl borane derivative, a bis (fluoroaryl) borane derivative, and a hydrocarbon solvent and is subjected to first filtration so that the fluoroaryl borane derivative is isolated, a filtrate that has been obtained by the first filtration is cooled and the bis (fluoroaryl) borane derivative is separated and is subjected to second filtration so that the bis (fluoroaryl) borane derivative is isolated. In a case where the solution contains fluorobenzene, the solution is concentrated, so that the fluorobenzene is removed. Thus, it is possible to provide the high-purity fluoroaryl borane derivative and bis (fluoroaryl) borane derivative having no impurity with ease and at a low cost.

Abstract: The present invention is concerned with a novel process for the preparation of 1-(3,5-bis(trifluoromethyl)phenyl)ethan-1-one (CAS 30071-93-3). This compound is useful as an intermediate in the synthesis of therapeutic agents.

Abstract: Polysubstituted indan-1-ol compounds of formula I, its physiologically acceptable salts and physiologically functional derivatives are disclosed Compositions comprising the same, methods of preparation and methods for the prophylaxis or treatment of obesity are also disclosed herein.

Abstract: Polysubstituted indan-1-ol compounds of formula I, its physiologically acceptable salts and physiologically functional derivatives are disclosed Compositions comprising the same, methods of preparation and methods for the prophylaxis or treatment of obesity are also disclosed herein.

Abstract: Use of phosphorous organic compounds of general formula (I) wherein B represents either an ether group of the formula (II) or a keto group of the formula (III) or is a 5 or 6 membered cyclic compound, and their use for preparing pharmaceutical compositions for the therapeutic and prophylactic treatment of infections in humans and animals due to viruses, bacteria, fungi, and parasites as well as their use as a fungicide, bactericide and herbicide in plants.

Abstract: The present invention relates to a process for producing an allyl sulfone derivative represented by the formula (3): wherein Ar is an optionally substituted aryl group, and the corrugated line means either one of E/Z geometrical isomers, or a mixture thereof, which is an intermediate for producing vitamin A, which process is characterized by reacting an aryl sulfinic acid or a salt thereof represented by the formula (2): ArSO2M  (2) wherein Ar is as defined above, and M is hydrogen atom, sodium atom or potassium atom, with an allyl halide derivative represented by the formula (1): wherein X is a halogen atom, and Ar and the corrugated line are as defined above.

Abstract: There is described the use of indoline derivatives of formula wherein R1 is hydrogen; C1-C5alkyl; C1-C18alkoxy; or halogen; R2 is C1-C8alkyl; C5-C7cycloalkyl; C6-C10aryl; R3 is C1-C18alkyl or a radical of formula (1a) R4 is hydrogen; or a radical of formula R5 is C1-C18alkoxy; or a radical of formula R6 and R7 are each independently of the other hydrogen; or C1-C5alkyl; R8 is hydrogen; C1-C5alkyl; C5-C7cycloalkyl; phenyl; phenyl-C1-C3alkyl; R9 is C1-C18alkyl; X is halogen; a radical of formula (1c) and n is 0; or 1, as light-protective agents.

Abstract: Novel reactions used to prepare phosphole and bisphosphole compounds are detailed. Novel phosphole compounds and metal coordination compounds of phosphole and bisphosphole compounds are also provided. These metal coordination compounds are useful as catalysts for the polymerization or olefins with carbon monoxide and for the polymerization of acrylic monomers.

Abstract: The invention relates to a process for the preparation of an organic boronic acid derivative comprising reacting a penta- or hexa-substituted diboron derivative with an organic compound having a halogen or halogen-like substituent at a coupling position in the presence of a Group VIII metal catalyst, such that a direct carbon to boron bond is formed between said coupling position and a boron-containing residue of the penta- or hexa-substituted diboron derivative.